Health Canada genehmigt Yorvipath von Ascendis Pharma für die Behandlung von chronischem Hypoparathyreoidismus

+0.51% Pre

+2.18% Pre

Ascendis Pharma A/S Sponsored ADR

ASND

242.95

+0.51%

0.00% Pre

Bank of New York Mellon Corp

134.84

+2.18%

0.00% Pre

Health Canada hat Yorvipath® (palopegteriparatide injection) für die Behandlung des chronischen Hypoparathyreoidismus bei Erwachsenen zugelassen. Ascendis Pharma A/S hat das Produkt entwickelt. Pendopharm ist für die regulatorische Zulassung und Vermarktung von Yorvipath® in Kanada verantwortlich. Die Zulassung basiert auf einer exklusiven Vertriebsvereinbarung zwischen Pendopharm und Ascendis Pharma, die im Juli 2024 unterzeichnet wurde.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via CNW (Ref. ID: C1596) on February 06, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.